HANGZHOU, China, July 8, 2026 /PRNewswire/ — On July 8, the study of Betta’s ensartinib as postoperative adjuvant therapy for patients with stage IB–IIIB (T3N2M0) ALK-positive non-small cell lung cancer (NSCLC), known as the ELEVATE study, was published online in full in The New England…
Source: prnewswire
Country: United States